Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jiangxi Institute of Biological Products Gross Margin %?
Jiangxi Institute of Biological ProductsHKSE:06915 +1.33%23 Gross Margin % is 76.75% as of Dec. 2025, which is 9% above its 10-year median of 70.28. GuruFocus rates HKSE:06915 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 940 Drug Manufacturers companies, Jiangxi Institute of Biological Products ranks better than 89.26% on this metric.
HKSE:06915's Gross Margin % is ranked better than 89.26% of 940
companies
in the Drug Manufacturers industry
Industry Median: 48.45
vs HKSE:06915: 76.75
Jiangxi Institute of Biological Products had a gross margin of 76.75% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Jiangxi Institute of Biological Products (HKSE:06915) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Jiangxi Institute of Biological Products had a gross margin of 76.75% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Jiangxi Institute of Biological Products Gross Margin % Related Terms
Jiangxi Institute of Biological Products Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Institute of Biological Products Gross Margin % Chart
Jiangxi Institute of Biological Products Annual Data
Trend
Dec23
Dec24
Dec25
Gross Margin %
67.82
70.28
76.75
Jiangxi Institute of Biological Products Semi-Annual Data
Dec23
Dec24
Dec25
Gross Margin %
67.82
70.28
76.75
HKSE:06915 vs LLY, JNJ, ABBV: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, Jiangxi Institute of Biological Products's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Institute of Biological Products Gross Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Jiangxi Institute of Biological Products (HKSE:06915) has a Gross Margin % of 76.75% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Jiangxi Institute of Biological Products and its competitors. This is near median its historical median of 70.28. Over the past decade, Jiangxi Institute of Biological Products' Gross Margin % has ranged from 67.82 to 76.75. According to the industry distribution chart, Jiangxi Institute of Biological Products ranks #101 out of 940 companies in the Drug Manufacturers industry, placing it in the top 10.7%.
Is Jiangxi Institute of Biological Products' Gross Margin % too high?
Jiangxi Institute of Biological Products' current Gross Margin % of 76.75% is near median its 10-year median of 70.28. Over the past 10 years, this metric has ranged from a low of 67.82 to a high of 76.75. The Drug Manufacturers industry median Gross Margin % is 48.45. Jiangxi Institute of Biological Products' value of 76.75% is 58.4% above this industry median. Based on the distribution chart, Jiangxi Institute of Biological Products ranks #101 out of 940 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangxi Institute of Biological Products has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Institute of Biological Products' Gross Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Jiangxi Institute of Biological Products ranks #101 out of 940 companies for Gross Margin %. This places Jiangxi Institute of Biological Products in the top 11% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.45. Jiangxi Institute of Biological Products' value of 76.75% is 58.4% above this benchmark. Historically, Jiangxi Institute of Biological Products' own Gross Margin % has ranged from 67.82 to 76.75 over the past decade. While the company's 10-year median is 70.28 vs. the industry median of 48.45, Jiangxi Institute of Biological Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.45, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangxi Institute of Biological Products's current Gross Margin % of 76.75% is 58.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Jiangxi Institute of Biological Products and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Institute of Biological Products's current Gross Margin % is 76.75%, which is near median its own 10-year median of 70.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Institute of Biological Products stock overvalued right now?
Jiangxi Institute of Biological Products (HKSE:06915) has a current Gross Margin % of 76.75%. The current Gross Margin % is 76.75%, which is near median its 10-year median of 70.28 and 58.4% above the Drug Manufacturers industry median of 48.45. Jiangxi Institute of Biological Products' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Jiangxi Institute of Biological Products (HKSE:06915), the current Gross Margin % is 76.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
23GF Score
Get the complete analysis for HKSE:06915
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06915 has been successfully added to your 
